Nymox Pharmaceutical Corporation Company Profile (NASDAQ:NYMX)

About Nymox Pharmaceutical Corporation (NASDAQ:NYMX)

Nymox Pharmaceutical Corporation logoNymox Pharmaceutical Corporation, formerly Corporation Pharmaceutique Nymox, is a biopharmaceutical company. The Company is focused on developing its drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia (BPH) and the treatment of low-grade localized prostate cancer. The Company markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. The Company also has a patent portfolio covering its marketed products, its investigational drug, as well as other therapeutic and diagnostic indications. The Company also has the United States and global patent rights for the use of statin drugs for the treatment and prevention of Alzheimer's disease. The Company's subsidiaries include Nymox Corporation and Serex, Inc. Nymox Corporation conducts research and development, while Serex conducts research and development, and manufacturing for NicAlert and TobacAlert.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Diagnostic Substances
  • Sub-Industry: N/A
  • Symbol: NASDAQ:NYMX
  • CUSIP: N/A
  • Web: www.nymox.com
Capitalization:
  • Market Cap: $206.85 million
  • Outstanding Shares: 52,368,000
Average Prices:
  • 50 Day Moving Avg: $3.86
  • 200 Day Moving Avg: $3.94
  • 52 Week Range: $2.67 - $5.10
P/E:
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $180,185.00
  • Price / Sales: 1,153.82
  • Book Value: ($0.01) per share
  • Price / Book: -397.00
Profitability:
  • EBITDA: ($11,190,000.00)
  • Net Margins: -6,412.29%
  • Return on Assets: -684.23%
Debt:
  • Debt-to-Equity Ratio: -0.92%
  • Current Ratio: 0.94%
  • Quick Ratio: 0.94%
Misc:
  • Average Volume: 102,767 shs.
  • Beta: 0.83
  • Short Ratio: 23.92
 

Frequently Asked Questions for Nymox Pharmaceutical Corporation (NASDAQ:NYMX)

What is Nymox Pharmaceutical Corporation's stock symbol?

Nymox Pharmaceutical Corporation trades on the NASDAQ under the ticker symbol "NYMX."

How were Nymox Pharmaceutical Corporation's earnings last quarter?

Nymox Pharmaceutical Corporation (NASDAQ:NYMX) posted its quarterly earnings data on Friday, November, 14th. The company reported ($0.02) earnings per share for the quarter. The business had revenue of $0.08 million for the quarter. View Nymox Pharmaceutical Corporation's Earnings History.

When will Nymox Pharmaceutical Corporation make its next earnings announcement?

Nymox Pharmaceutical Corporation is scheduled to release their next quarterly earnings announcement on Tuesday, November, 21st 2017. View Earnings Estimates for Nymox Pharmaceutical Corporation.

Are investors shorting Nymox Pharmaceutical Corporation?

Nymox Pharmaceutical Corporation saw a decrease in short interest during the month of September. As of September 29th, there was short interest totalling 1,179,164 shares, a decrease of 63.6% from the September 15th total of 3,242,584 shares. Based on an average trading volume of 85,710 shares, the days-to-cover ratio is currently 13.8 days. Currently, 3.9% of the shares of the stock are sold short.

Who are some of Nymox Pharmaceutical Corporation's key competitors?

How do I buy Nymox Pharmaceutical Corporation stock?

Shares of Nymox Pharmaceutical Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Nymox Pharmaceutical Corporation's stock price today?

One share of Nymox Pharmaceutical Corporation stock can currently be purchased for approximately $3.97.


MarketBeat Community Rating for Nymox Pharmaceutical Corporation (NASDAQ NYMX)
Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  32 (Vote Outperform)
Underperform Votes:  37 (Vote Underperform)
Total Votes:  69
MarketBeat's community ratings are surveys of what our community members think about Nymox Pharmaceutical Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Nymox Pharmaceutical Corporation (NASDAQ:NYMX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A
Consensus Price Target History for Nymox Pharmaceutical Corporation (NASDAQ:NYMX)
Price Target History for Nymox Pharmaceutical Corporation (NASDAQ:NYMX)
Analysts' Ratings History for Nymox Pharmaceutical Corporation (NASDAQ:NYMX)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for Nymox Pharmaceutical Corporation (NASDAQ:NYMX)
Earnings by Quarter for Nymox Pharmaceutical Corporation (NASDAQ:NYMX)
Earnings History by Quarter for Nymox Pharmaceutical Corporation (NASDAQ NYMX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/21/2017        
11/14/2014Q314($0.02)$0.08 millionViewN/AView Earnings Details
11/13/2013Q3($0.03)ViewN/AView Earnings Details
5/15/2013Q1 2013($0.05)($0.03)$0.78 million$0.18 millionViewN/AView Earnings Details
11/14/2012Q312($0.06)($0.04)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Nymox Pharmaceutical Corporation (NASDAQ:NYMX)

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Nymox Pharmaceutical Corporation (NASDAQ:NYMX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Nymox Pharmaceutical Corporation (NASDAQ:NYMX)
Insider Ownership Percentage: 54.00%
Institutional Ownership Percentage: 5.79%
Insider Trades by Quarter for Nymox Pharmaceutical Corporation (NASDAQ:NYMX)
Institutional Ownership by Quarter for Nymox Pharmaceutical Corporation (NASDAQ:NYMX)
Insider Trades by Quarter for Nymox Pharmaceutical Corporation (NASDAQ:NYMX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/3/2017James George RobinsonDirectorBuy10,000$3.73$37,300.00View SEC Filing  
8/2/2017James George RobinsonDirectorBuy5,000$3.79$18,950.00View SEC Filing  
8/1/2017James George RobinsonDirectorBuy15,000$3.72$55,800.00View SEC Filing  
7/7/2017James George RobinsonDirectorBuy11,500$4.00$46,000.00View SEC Filing  
7/6/2017James George RobinsonDirectorBuy3,000$3.92$11,760.00View SEC Filing  
7/5/2017James George RobinsonDirectorBuy5,000$3.97$19,850.00View SEC Filing  
6/28/2017James George RobinsonDirectorBuy8,500$4.09$34,765.00View SEC Filing  
6/26/2017James George RobinsonDirectorBuy15,000$3.80$57,000.00View SEC Filing  
6/21/2017James George RobinsonDirectorBuy15,000$3.77$56,550.00View SEC Filing  
6/20/2017James George RobinsonDirectorBuy5,000$3.76$18,800.00View SEC Filing  
6/19/2017James George RobinsonDirectorBuy5,000$3.79$18,950.00View SEC Filing  
5/30/2017James George RobinsonDirectorBuy54,500$3.81$207,645.00View SEC Filing  
3/8/2017James George RobinsonDirectorBuy50,000$3.59$179,500.00View SEC Filing  
8/10/2016James George RobinsonDirectorBuy500$2.47$1,235.00View SEC Filing  
8/4/2016James George RobinsonDirectorBuy7,000$3.41$23,870.00View SEC Filing  
7/29/2016James George RobinsonDirectorBuy22,500$3.86$86,850.00View SEC Filing  
7/20/2016James George RobinsonDirectorBuy10,000$3.33$33,300.00View SEC Filing  
7/7/2016James George RobinsonDirectorBuy20,000$3.28$65,600.00View SEC Filing  
6/29/2016James George RobinsonDirectorBuy17,500$3.53$61,775.00View SEC Filing  
6/24/2016James George RobinsonDirectorBuy22,500$2.97$66,825.00View SEC Filing  
5/13/2016James George RobinsonDirectorBuy28,010$2.31$64,703.10View SEC Filing  
5/3/2016James George RobinsonDirectorBuy6,990$2.36$16,496.40View SEC Filing  
4/29/2016James George RobinsonDirectorBuy15,000$2.27$34,050.00View SEC Filing  
4/15/2016James George RobinsonDirectorBuy39,500$2.39$94,405.00View SEC Filing  
4/1/2016James George RobinsonDirectorBuy20,500$2.40$49,200.00View SEC Filing  
3/24/2016James George RobinsonDirectorBuy40,000$2.29$91,600.00View SEC Filing  
1/12/2016James George RobinsonDirectorBuy20,000$2.44$48,800.00View SEC Filing  
1/8/2016James George RobinsonDirectorBuy95,000$2.90$275,500.00View SEC Filing  
12/30/2015James George RobinsonDirectorBuy5,000$3.38$16,900.00View SEC Filing  
12/29/2015James George RobinsonDirectorBuy14,000$3.55$49,700.00View SEC Filing  
12/28/2015James George RobinsonDirectorBuy6,000$3.79$22,740.00View SEC Filing  
12/23/2015James George RobinsonDirectorBuy29,854$3.54$105,683.16View SEC Filing  
12/18/2015James George RobinsonDirectorBuy63,334$3.56$225,469.04View SEC Filing  
12/11/2015James George RobinsonDirectorBuy46,812$3.51$164,310.12View SEC Filing  
12/4/2015James George RobinsonDirectorBuy110,000$3.44$378,400.00View SEC Filing  
9/3/2015James George RobinsonDirectorBuy100,000$2.25$225,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Nymox Pharmaceutical Corporation (NASDAQ:NYMX)
Latest Headlines for Nymox Pharmaceutical Corporation (NASDAQ:NYMX)
Source:
DateHeadline
globenewswire.com logoNymox Reports on Symposium, Panel Discussion with Abstract on Fexapotide at American Urological Association Northeast ...
globenewswire.com - October 14 at 6:23 AM
finance.yahoo.com logoNymox Reports on Symposium, Panel Discussion with Abstract on Fexapotide at American Urological Association Northeast Sectional Annual Meeting in Savannah
finance.yahoo.com - October 14 at 6:23 AM
americanbankingnews.com logoNymox Pharmaceutical Corporation (NYMX) Sees Significant Decrease in Short Interest
www.americanbankingnews.com - October 14 at 1:40 AM
thestreet.com logoShort Interest Falls 63.6% For NYMX
www.thestreet.com - October 12 at 7:45 AM
globenewswire.com logoNymox Reports on Symposium and Panel Discussion on Fexapotide at American Urological Association Northeast Sectional ...
globenewswire.com - October 11 at 5:52 AM
finance.yahoo.com logoNymox Announces October 12 Symposium for Company's BPH Drug at American Urological Association Meeting
finance.yahoo.com - October 2 at 7:25 PM
streetinsider.com logoNymox Pharma (NYMX) Says Its MAA For Fexapotide Triflutate was Validated - StreetInsider.com
www.streetinsider.com - September 15 at 7:03 AM
finance.yahoo.com logoNymox Announces New Symposium for Company's BPH Drug at American Urological Association Meeting October 5
finance.yahoo.com - September 15 at 7:03 AM
finance.yahoo.com logoNymox Application Validated:
finance.yahoo.com - September 15 at 7:03 AM
finance.yahoo.com logoAUA Meeting in Florida September 16 Postponed Due to Hurricane
finance.yahoo.com - September 12 at 7:40 AM
finance.yahoo.com logoETFs with exposure to Nymox Pharmaceutical Corp. : September 12, 2017
finance.yahoo.com - September 12 at 7:40 AM
finance.yahoo.com logoETFs with exposure to Nymox Pharmaceutical Corp. : August 31, 2017
finance.yahoo.com - September 1 at 6:37 AM
finance.yahoo.com logoNymox Pharmaceutical Corp. :NYMX-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
finance.yahoo.com - August 25 at 9:32 AM
finance.yahoo.com logoNymox Announces Private Placements of $3 Million
finance.yahoo.com - August 10 at 6:23 AM
nasdaq.com logoNymox Announces Symposium for Company's BPH Drug at ... - Nasdaq
www.nasdaq.com - August 8 at 2:39 AM
americanbankingnews.com logoNymox Pharmaceutical Corporation (NASDAQ:NYMX) Director James George Robinson Acquires 10,000 Shares
www.americanbankingnews.com - August 4 at 9:00 PM
americanbankingnews.com logoInsider Buying: Nymox Pharmaceutical Corporation (NASDAQ:NYMX) Director Buys 5,000 Shares of Stock
www.americanbankingnews.com - August 4 at 9:00 PM
finance.yahoo.com logoETFs with exposure to Nymox Pharmaceutical Corp. : August 4, 2017
finance.yahoo.com - August 4 at 6:32 AM
americanbankingnews.com logoNymox Pharmaceutical Corporation (NASDAQ:NYMX) Director James George Robinson Acquires 15,000 Shares
www.americanbankingnews.com - August 1 at 8:21 PM
americanbankingnews.com logoNymox Pharmaceutical Corporation (NYMX) Director James George Robinson Buys 11,500 Shares
www.americanbankingnews.com - July 7 at 9:03 PM
americanbankingnews.com logoNymox Pharmaceutical Corporation (NYMX) Director James George Robinson Acquires 5,000 Shares
www.americanbankingnews.com - July 7 at 9:02 PM
americanbankingnews.com logoInsider Buying: Nymox Pharmaceutical Corporation (NASDAQ:NYMX) Director Acquires 3,000 Shares of Stock
www.americanbankingnews.com - July 7 at 9:02 PM
thestreet.com logoCommit To Purchase Nymox Pharmaceutical Corp At $3, Earn 25% Using Options
www.thestreet.com - July 6 at 7:37 AM
finance.yahoo.com logoETFs with exposure to Nymox Pharmaceutical Corp. : July 4, 2017
finance.yahoo.com - July 5 at 9:08 AM
globenewswire.com logoSexual Function Improves in First-Line Patients Given Fexapotide Treatment in Nymox U.S. BPH Long-Term Clinical ... - GlobeNewswire (press release)
globenewswire.com - May 31 at 11:29 AM
globenewswire.com logoNYMOX Files For Approval of First In Class Prostate Drug in Europe: Teleconference at 4:30 ...
globenewswire.com - May 12 at 12:29 AM
feeds.benzinga.com logoNYMOX Files For Approval of First In Class Prostate Drug in Europe: Teleconference at 4:30 EDT
feeds.benzinga.com - May 10 at 11:37 AM
globenewswire.com logoNYMOX Files For Marketing Approval For Fexapotide Triflutate in Europe - GlobeNewswire (press release)
globenewswire.com - May 3 at 8:06 PM
nasdaq.com logoBUZZ-US STOCKS ON THE MOVE-Vertex Pharma, Morgan Stanley, F5, Exar, Tonix Pharma, Vertex - Nasdaq
www.nasdaq.com - March 29 at 7:38 PM
247wallst.com logo5 Biohealth Stocks Rising 10% or More on News
247wallst.com - March 1 at 10:26 AM
thestreet.com logoNymox Pharmaceuticals (NYMX) Stock Surges on Prostate Drug Progress
www.thestreet.com - March 1 at 10:26 AM
thestreet.com logoNymox Pharmaceuticals (NYMX) Stock Surges on Long-Term Prostate Drug Trial Success
www.thestreet.com - March 1 at 10:26 AM
thestreet.com logoJabbing a Needle in the Overinflated Nymox Prostate Drug Hype
www.thestreet.com - March 1 at 10:26 AM
reuters.com logoProfile: Nymox Pharmaceutical Corp (NYMX.OQ)
www.reuters.com - January 28 at 7:04 PM
investorplace.com logoHottest Manufacturing Stocks Now – FOLD AQXP NLNK ACHN - Investorplace.com
investorplace.com - December 27 at 9:57 AM

Social

Chart

Nymox Pharmaceutical Corporation (NYMX) Chart for Thursday, October, 19, 2017

This page was last updated on 10/19/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.